-- Robert Preidt
THURSDAY, Nov. 1 (HealthDay News) -- The cancer drug alemtuzumab
(Campath) reduces the risk of disease relapse in people with
multiple sclerosis, two new trials show.
About 85 percent of multiple sclerosis patients start with a
form of the disease called relapsing-remitting MS, where symptoms
appear sporadically (a relapse) and then either partially or
completely fade away. There is no cure for MS, and existing drugs
only aim to reduce the symptoms of the disease.
MS occurs when the body's immune system starts to attack the
coating of nerve fibers. Alemtuzumab, which is used to treat
leukemia and other cancers of the immune system, works by altering
the number, proportions and functions of certain types of
lymphocytes, which are white blood cells that play a major role in
the functioning of the immune system.
In these two clinical trials, British researchers led by
Alastair Compston of the University of Cambridge compared
alemtuzumab with interferon beta 1a, the most common drug used to
The first trial included patients who had never received drug
treatment for MS. The relapse rates after two years were 22 percent
for those who were given alemtuzumab and 40 percent for those who
were given interferon beta 1a.
The second trial included patients who had already been treated
with either interferon beta 1a or another MS drug called
glatiramer, but had suffered at least one relapse since their
initial treatment. The relapse rates were 35 percent for patients
who were given alemtuzumab and 51 percent for those who received
interferon beta 1a, the investigators found.
The researchers also found that alemtuzumab appeared to reduce
the risk of MS-related disability such as the loss of coordination
or the ability to walk. Disability rates were 13 percent among
those in the alemtuzumab group and 20 percent of those in the
interferon beta 1a group. The first trial found no significant
difference in disability rates between the two groups of
In both trials, alemtuzumab appeared to increase the risk of
certain autoimmune disorders, particularly those affecting the
thyroid. These side effects are potentially serious but can be
treated, the researchers noted.
The findings were published Oct. 31 in
The findings are "encouraging," according to a journal
editorial, which noted that alemtuzumab has been used off-label for
many years to treat MS patients.
"These trials have been keenly awaited by clinicians and patients wishing to establish evidence for this practice. . . . However, there is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients [and health systems]," the editorial stated.
"Finding promising treatments such as alemtuzumab is important. But so is keeping alemtuzumab accessible and affordable if its early success in these trials proves to be of enduring value," the editorial concluded.
The U.S. National Institute of Neurological Disorders and Stroke
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.